Read if you want one stock you can retire on

[brucefan]

​

Predictive Technology Group Reports Second Quarter Fiscal 2020 Financial Results and Provides Corporate Update

Email Print Friendly Share
February 14, 2020 16:26 ET | Source: Predictive Technology Group Inc


SALT LAKE CITY, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Predictive Technology Group (OTC PINK: PRED) (“Predictive” or “The Company”), a leader in helping identify barriers that impact women’s health and build healthier families through its innovations to deliver personalized medicine, today announced financial results for the fiscal second quarter ended December 31, 2019 and provided a corporate update.

Management Commentary
“During the fiscal second quarter and subsequent period, we made significant progress toward our goal of becoming a leading developer of diagnostics and therapeutics targeting the women’s health and fertility markets,” said Bradley C. Robinson, Chief Executive Officer of Predictive Technologies Group. “The clear highlight since our last quarterly report is the announcement last month that we entered into a broad molecular diagnostic oncology development collaboration with Atrin Pharmaceuticals to develop diagnostic tools to facilitate improved selection of cancer patients who would most benefit from treatment with Atrin’s DNA Damage and Response inhibitors and other small molecule ATR inhibitors. This first-of-its-kind collaboration opens significant new markets for our state-of-the-art sequencing capabilities, genomics expertise and companion diagnostics and, we believe, establishes a framework for additional collaborations in the future.”
“At the same time, market uptake for our recently introduced diagnostic tests, including FertilityDX™ and ARTguide™, is exceeding our expectations, reflecting the significant unmet needs that exist for accurate tests that can help patients and their doctors identify risk factors and barriers to pregnancy and develop tailored fertility treatments.”
“We did anticipate some softness in our Predictive Biotech business during the quarter, driven by heightened FDA regulation of human cell and tissue products, and the regenerative medicine industry as a whole, which we believe caused a contraction across the market and a year-over-year decline in our Predictive Biotech revenue. Total company revenue for the quarter was $7.3 million, down about $3.4 million from $10.7 million that was reported fiscal second quarter of 2018. Notwithstanding this temporary headwind, however, we see significant value in the Biotech business, and we are the clear industry leader with an excellent safety and quality record of over 100,000 allografts implanted with no adverse events.”
Mr. Robinson concluded, “As we enter the back half of our fiscal year, we continue to execute on our growth plan, and we believe that our emergence as a women’s health leader, together with our anticipated up-listing to the Nasdaq exchange, will unlock significant long-term value for our shareholders.”
Fiscal Second Quarter and Recent Highlights

• Announced positive interim beta test results on over 1,000 patients tested with ARTguide™ at Houston Fertility Institute. Initial test results exceed all expectations and parameters established during research and development and prospective data continue to accumulate regarding pregnancy rates and other treatment outcomes.
• In January, announcement of a molecular diagnostic oncology development collaboration with Atrin Pharmaceuticals to develop diagnostic tools to facilitate improved selection of cancer patients who would most benefit from treatment with Atrin’s DNA Damage and Response inhibitors and other small molecule ATR inhibitors
• In October, announced the successful U.S. launch of FertilityDX™, a comprehensive genetic testing service that identifies barriers to healthy pregnancy and birth, allowing doctors to tailor fertility treatments
• Continued to work to satisfy Nasdaq listing requirements with the goal of up-listing PRED shares to the Nasdaq exchange

Fiscal Second Quarter 2020 Results
Revenues from operations (net) for the three months ended December 31, 2019 totaled $7.3 million, compared with $10.7 million for the three months ended December 31, 2018. The decrease of $3.4 million was primarily due to the decline in sales volume of allograft products as compared to the year-ago period. The decrease in sales volume is due to increased FDA enforcement efforts affecting the regenerative medicine industry as a whole, which has negatively impacted the size of the market for regenerative medicine services and caused a contraction of sales of allograft products.
Cost of goods sold (“COGS”) for the three months ended December 31, 2019 was $5.8 million (or 79.6% of revenue) compared with $3.1 million (or 28.6% of revenue) for the three months ended December 31, 2018. The increase in COGS is primarily due to $1.9 million in scrap expense and idle capacity costs resulting from efforts to curtail production in response to the trend in allograft sales. In addition, there was a $0.8 million increase in scrap expense due to a decrease in average quality control pass rates for WIP product compared to the three months ended December 31, 2018.
Sales and marketing expenses for the three months ended December 31, 2019 were $3.0 million, compared with $3.4 million for the three months ended December 31, 2018. The decrease in sales and marketing expense was due to lower paid commissions, as a majority of the company’s sales and marketing expenses are incurred in the HCT/P segment.
Research and development (R&D) expenses for the three months ended December 31, 2019 were $2.4 million, compared with $1.8 million for the three months ended December 31, 2018, the increase was primarily related to the development of new allograft products and continued development of molecular diagnostic tests.
General and Administrative (G&A) expenses for the three months ended December 31, 2019 were $7.0 million compared with $2.9 million for the three months ended December 31, 2018. Approximately $3.3 million of the increase is due to increased share-based compensation expenses. Personnel costs also increased by $0.6 million.
Amortization and depreciation expenses for the three months ended December 31, 2019 were $2.8 million, compared with $2.0 million for the three months ended December 31, 2018. The increase was driven by growth in the company’s intangible asset portfolio arising from business combinations and asset acquisitions.
Other loss for the three months ended December 31, 2019 increased to $16.5 million from $0.6 million for the three months ended December 31, 2018. The increase was primarily driven by the recognition of an impairment charge of $15.9 million on our equity method investment in Juneau Biosciences, LLC as part of a broader impairment review triggered by the recent decline in the Company's stock price.
The net loss attributable to controlling interest for the three months ended December 31, 2019 was $26.0 million, or $0.09 per share, versus a net loss attributable to controlling interest for the three months ended December 31, 2018 of $2.3 million, or $0.01 per share.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics. For more information, visit www.predtechgroup.com.
Forward-Looking Statements:
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contacts:
For more information, visit www.predtechgroup.com or contact Investor Relations:
Media Contact
Patrick Bursey
LifeSci Public Relations
pbursey@lifescipublicrelations.com
646-876-4932
Investor Contact
Jeremy Feffer
LifeSci Advisors
jeremy@lifesciadvisors.com
212-915-2568

 

[brucefan]

Using Genetic Testing to Advance Healthcare for Womenwith Brad Robinson Predictive Technology GroupAn Empowered Patient Podcast Published February 12, 2020


https://hwcdn.libsyn.com/p/1/6/d/16d1dc846f87b6dd/Empowered_Patient_Podcast_Brad_Robinson_Predictive_TRANSCRIPT.pdf?c_id=64649885&cs_id=64649885&destination_id=500706&expiration=1581599542&hwt=7750d662a884eaa1bb82c8095361f3a5

 

[flashmo]

​

Predictive Technology Group Reports Second Quarter Fiscal 2020 Financial Results and Provides Corporate Update

Email Print Friendly Share
February 14, 2020 16:26 ET | Source: Predictive Technology Group Inc


SALT LAKE CITY, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Predictive Technology Group (OTC PINK: PRED) (“Predictive” or “The Company”), a leader in helping identify barriers that impact women’s health and build healthier families through its innovations to deliver personalized medicine, today announced financial results for the fiscal second quarter ended December 31, 2019 and provided a corporate update.

Management Commentary
“During the fiscal second quarter and subsequent period, we made significant progress toward our goal of becoming a leading developer of diagnostics and therapeutics targeting the women’s health and fertility markets,” said Bradley C. Robinson, Chief Executive Officer of Predictive Technologies Group. “The clear highlight since our last quarterly report is the announcement last month that we entered into a broad molecular diagnostic oncology development collaboration with Atrin Pharmaceuticals to develop diagnostic tools to facilitate improved selection of cancer patients who would most benefit from treatment with Atrin’s DNA Damage and Response inhibitors and other small molecule ATR inhibitors. This first-of-its-kind collaboration opens significant new markets for our state-of-the-art sequencing capabilities, genomics expertise and companion diagnostics and, we believe, establishes a framework for additional collaborations in the future.”
“At the same time, market uptake for our recently introduced diagnostic tests, including FertilityDX™ and ARTguide™, is exceeding our expectations, reflecting the significant unmet needs that exist for accurate tests that can help patients and their doctors identify risk factors and barriers to pregnancy and develop tailored fertility treatments.”
“We did anticipate some softness in our Predictive Biotech business during the quarter, driven by heightened FDA regulation of human cell and tissue products, and the regenerative medicine industry as a whole, which we believe caused a contraction across the market and a year-over-year decline in our Predictive Biotech revenue. Total company revenue for the quarter was $7.3 million, down about $3.4 million from $10.7 million that was reported fiscal second quarter of 2018. Notwithstanding this temporary headwind, however, we see significant value in the Biotech business, and we are the clear industry leader with an excellent safety and quality record of over 100,000 allografts implanted with no adverse events.”
Mr. Robinson concluded, “As we enter the back half of our fiscal year, we continue to execute on our growth plan, and we believe that our emergence as a women’s health leader, together with our anticipated up-listing to the Nasdaq exchange, will unlock significant long-term value for our shareholders.”
Fiscal Second Quarter and Recent Highlights

• Announced positive interim beta test results on over 1,000 patients tested with ARTguide™ at Houston Fertility Institute. Initial test results exceed all expectations and parameters established during research and development and prospective data continue to accumulate regarding pregnancy rates and other treatment outcomes.
• In January, announcement of a molecular diagnostic oncology development collaboration with Atrin Pharmaceuticals to develop diagnostic tools to facilitate improved selection of cancer patients who would most benefit from treatment with Atrin’s DNA Damage and Response inhibitors and other small molecule ATR inhibitors
• In October, announced the successful U.S. launch of FertilityDX™, a comprehensive genetic testing service that identifies barriers to healthy pregnancy and birth, allowing doctors to tailor fertility treatments
• Continued to work to satisfy Nasdaq listing requirements with the goal of up-listing PRED shares to the Nasdaq exchange

Fiscal Second Quarter 2020 Results
Revenues from operations (net) for the three months ended December 31, 2019 totaled $7.3 million, compared with $10.7 million for the three months ended December 31, 2018. The decrease of $3.4 million was primarily due to the decline in sales volume of allograft products as compared to the year-ago period. The decrease in sales volume is due to increased FDA enforcement efforts affecting the regenerative medicine industry as a whole, which has negatively impacted the size of the market for regenerative medicine services and caused a contraction of sales of allograft products.
Cost of goods sold (“COGS”) for the three months ended December 31, 2019 was $5.8 million (or 79.6% of revenue) compared with $3.1 million (or 28.6% of revenue) for the three months ended December 31, 2018. The increase in COGS is primarily due to $1.9 million in scrap expense and idle capacity costs resulting from efforts to curtail production in response to the trend in allograft sales. In addition, there was a $0.8 million increase in scrap expense due to a decrease in average quality control pass rates for WIP product compared to the three months ended December 31, 2018.
Sales and marketing expenses for the three months ended December 31, 2019 were $3.0 million, compared with $3.4 million for the three months ended December 31, 2018. The decrease in sales and marketing expense was due to lower paid commissions, as a majority of the company’s sales and marketing expenses are incurred in the HCT/P segment.
Research and development (R&D) expenses for the three months ended December 31, 2019 were $2.4 million, compared with $1.8 million for the three months ended December 31, 2018, the increase was primarily related to the development of new allograft products and continued development of molecular diagnostic tests.
General and Administrative (G&A) expenses for the three months ended December 31, 2019 were $7.0 million compared with $2.9 million for the three months ended December 31, 2018. Approximately $3.3 million of the increase is due to increased share-based compensation expenses. Personnel costs also increased by $0.6 million.
Amortization and depreciation expenses for the three months ended December 31, 2019 were $2.8 million, compared with $2.0 million for the three months ended December 31, 2018. The increase was driven by growth in the company’s intangible asset portfolio arising from business combinations and asset acquisitions.
Other loss for the three months ended December 31, 2019 increased to $16.5 million from $0.6 million for the three months ended December 31, 2018. The increase was primarily driven by the recognition of an impairment charge of $15.9 million on our equity method investment in Juneau Biosciences, LLC as part of a broader impairment review triggered by the recent decline in the Company's stock price.
The net loss attributable to controlling interest for the three months ended December 31, 2019 was $26.0 million, or $0.09 per share, versus a net loss attributable to controlling interest for the three months ended December 31, 2018 of $2.3 million, or $0.01 per share.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics. For more information, visit www.predtechgroup.com.
Forward-Looking Statements:
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.
Contacts:
For more information, visit www.predtechgroup.com or contact Investor Relations:
Media Contact
Patrick Bursey
LifeSci Public Relations
pbursey@lifescipublicrelations.com
646-876-4932
Investor Contact
Jeremy Feffer
LifeSci Advisors
jeremy@lifesciadvisors.com
212-915-2568

I assume this is why stock went down so much..Do you think the stock should be held on to?

 

[brucefan]

I assume this is why stock went down so much..Do you think the stock should be held on to?

I think it should be bought . To me, this one is all about the upside if, and when, Im right .

" Brad Robinson: And my brother helped him for about 10 years and then in 2008 I got to know Ken ward. I started helping him raise a little bit of money, got more involved. Now all of our friends, very sophisticated friends that are fromthe healthcare industry, put in about $50 million. We do not have venture capital. We have not done a public offering. We don't have private equity or venture funds. There are people that are very sophisticated, very passionate about this. A good example is Ron Barhorstwas an early investor. He was the CEO of ING Financial, his wife had endometriosis, four laparoscopies, fluoroscopy, hysterectomy, no children. They're very successful people. They're passionate about these areas. It's personal to all of us. We're not women, but we have wives and daughters and they deserve to be empowered. And I commend you for what you're doing and trying to make this happen. "

 

[Ezdoesit]

The general public has not been able to sell 1 share since this report was released, therefore the price has not dropped because of the report, YET. This will be the reason for Tuesday's big drop. As far as holding onto this stock, would you have held onto Enron in late 2001?

 

[brucefan]

The general public has not been able to sell 1 share since this report was released, therefore the price has not dropped because of the report, YET. This will be the reason for Tuesday's big drop. As far as holding onto this stock, would you have held onto Enron in late 2001?

Thats a silly comparison not even worth addressing . Do you think they brought in Deloitte and Touche to expose their acct fraud ?

The stock dropped from a high of 1.24 on jan 8th, most likely fully discounting the report .

 

[okie77]

I have basically written this investment off as a loss. Did some homework on Brad Robinson. This guy really has a shady aura around him. His interviews reek of BS. His arrogance is impossible for him to mask. I've have just under 7k invested but my guess is Pred will be under. 40 before the end of the month. Likely worthless by the end of the year. Really hope I'm proven wrong but sadly I don't think so.

 

[MattyMatt]

I have basically written this investment off as a loss. Did some homework on Brad Robinson. This guy really has a shady aura around him. His interviews reek of BS. His arrogance is impossible for him to mask. I've have just under 7k invested but my guess is Pred will be under. 40 before the end of the month. Likely worthless by the end of the year. Really hope I'm proven wrong but sadly I don't think so.

I’ve said along he’s our weak link. I doubt big money is gonna trust this guy. I had to talk myself into investing here when I saw he was in charge.

Bad move on my part, hope to be proven wrong as well...

 

[fballgenius]

I have basically written this investment off as a loss. Did some homework on Brad Robinson. This guy really has a shady aura around him. His interviews reek of BS. His arrogance is impossible for him to mask. I've have just under 7k invested but my guess is Pred will be under. 40 before the end of the month. Likely worthless by the end of the year. Really hope I'm proven wrong but sadly I don't think so.

okie77, I hope you’re wrong too. I have 10K invested. A friend of mine told me to get out when it was $1.20 back in early January. He’s been calling it a “pump and dump” all along. I don’t even like looking at my portfolio anymore because all I focus on is Big Red Pred. $0.60 today. Could be zero pretty soon.

 

[MattyMatt]

okie77, I hope you’re wrong too. I have 10K invested. A friend of mine told me to get out when it was $1.20 back in early January. He’s been calling it a “pump and dump” all along. I don’t even like looking at my portfolio anymore because all I focus on is Big Red Pred. $0.60 today. Could be zero pretty soon.

Yep! Bruce pumped this one like he did GNAL! Thank gawd I told him it was garbage from the start. It’s barely worth a penny, and you may be right, this one might not be far behind...

 

[okie77]

Certainly not Bruce's fault. I had heard about this stock before he posted about it. No one to blame for my losses but me. I was lax in my due diligence. Had extra money lying around and took a flyer. My average buy price is down to $1.56 so it sure is tempting to pop another couple grand down at these prices. I still have hope but not much lol.

 

[MattyMatt]

Certainly not Bruce's fault. I had heard about this stock before he posted about it. No one to blame for my losses but me. I was lax in my due diligence. Had extra money lying around and took a flyer. My average buy price is down to $1.56 so it sure is tempting to pop another couple grand down at these prices. I still have hope but not much lol.

I didn’t nor am I blaming him for my losses, just pumping the shit out of it, and technically I haven’t lost a thing, my dumbass didn’t sell, in fact, I even averaged down myself in the .70s.

I honestly couldn’t care less about “retiring early” anymore, lol, if I can reach my average somehow miraculously, I’m most likely out...

I just don’t see it happening with Bradley Robinson at the helm, it just is what it is. There are some big names with this stock, no denying that, but how they don’t seem to give a damn is somewhat baffling to me...

Let us pray...

 

[brucefan]

Geez , ,what a depressing thread Read the title. I didn't pick this one out for what would happen in a year , or even two . Its been a wild ride and the only thing that I believe that has gone wrong is we didn't belong at 7 bucks , yet .

Especially since we never got listed

My target is 100 bucks, not 5 , 6 or 7, and unfortunately, I got smoked like lots of people here who didn't sell . Instead of stopping out, I loved the story so much, and was convinced an up listing was very close, that I just added at support levels that didn't hold .

So,..... ill have more when we run again . I paid 70 and 61 yesterday for more, as I try to bring my avg cost down . This company needs to execute its plan, and then we able to support the higher market cap

This company is a baby and they are on a mission, but that doesn't necessarily have anything to do with a near term stock price

Lets not forget we got a zachs report out with a price target of 8 or 9? I think it was . There are reasons people got excited about what the future holds for PRED, and that story has not been told yet

Its very hard for retail to hold a stock together when its under attack like we've been . On Nasdaq when funds can buy, different story

Lastly , this is a biotech stock ! They suck until they dont

 

[okie77]

I'm not disputing any of that Bruce. But can you honestly say when you watch any of Robinson's interviews that he doesn't come off as really shady? Just something aboutt the guy doesnt sit right with me. My gut feelings are usually spot on. His checkered past added on top of that just gives me cause for concern. One way or the other these 15% swings every day sure keep a guy interested.

 

[smartmoneyfollower]

I didn’t nor am I blaming him for my losses, just pumping the shit out of it, and technically I haven’t lost a thing, my dumbass didn’t sell, in fact, I even averaged down myself in the .70s.

I honestly couldn’t care less about “retiring early” anymore, lol, if I can reach my average somehow miraculously, I’m most likely out...

I just don’t see it happening with Bradley Robinson at the helm, it just is what it is. There are some big names with this stock, no denying that, but how they don’t seem to give a damn is somewhat baffling to me...

Let us pray...

Just when I think you are the poorest shit bag loser, you decide "Let us pray.." is you future trading strategy, I was laughing at ... "I honestly couldn’t care less about “retiring early” anymore", but "Let us pray.." was the icing on the cake. The greatest bull run, in the history of the longest bull market in history, and you can't scrape up more the 5K to invest per trade, you are a total shit show. Poor people just find ways to lose money, and you proved it, no matter how many chances they get, you stay poor.

 

[MattyMatt]

Just when I think you are the poorest shit bag loser, you decide "Let us pray.." is you future trading strategy, I was laughing at ... "I honestly couldn’t care less about “retiring early” anymore", but "Let us pray.." was the icing on the cake. The greatest bull run, in the history of the longest bull market in history, and you can't scrape up more the 5K to invest per trade, you are a total shit show. Poor people just find ways to lose money, and you proved it, no matter how many chances they get, you stay poor.

Lmao! You’re the douchebag fake that’s won’t take me up in my bet. It’s $20k on the line, should be chump change for you, right?!

You have no idea what I have. Losing this wasn’t a thing, I have a set amount I “gamble” on high risk stocks every year. This was it last year...I guess you conveniently missed the years before that when it was XXII, that got me an 18x return, and currently has me still up on the freebies I kept for the helluvit...

AMD, SMG, and even TSLA (hate their products, but love that money) have been fabulous for me, just like I knew they would...

CWGIX, SAND, and AG haven’t performed quite as well as I hoped they would, but still a nice come up...

GE has almost doubled for me off the bottom, and the dividend now sucks, but LMT has been fabulous as well, and their nice dividend has made up for it...

I’m still set to retire at the age I chose years ago, and my kids college is gonna be paid for along with a nice trust, so I’m perfectly fine...

Curious to see your post for the fights tonight, but don’t bother, everybody already knows, Mr. Juicy Juice...

You’d be better off just giving up already, everyone figured you out long ago...

 

[brucefan]

[h=1]Atrin Pharmaceuticals Adds Critical Genomics Capabilities in Advance of Initiating First Clinical Trial Through Ongoing Collaboration with Predictive Technology Group[/h][h=2][/h][FONT=&quot]https://www.globenewswire.com/news-...ration-with-Predictive-Technology-Group.html#[FONT=&quot][/FONT][FONT=&quot][/FONT][FONT=&quot][/FONT][FONT=&quot][/FONT][FONT=&quot][/FONT]Email [FONT=&quot][/FONT]Print Friendly [FONT=&quot][/FONT]Share
February 25, 2020 08:00 ET | Source: Predictive Technology Group Inc


DOYLESTOWN, Pa., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Atrin Pharmaceuticals, a private biopharmaceutical company pioneering the discovery and development of proprietary molecules targeting DNA Damage and Repair (DDR) pathways to treat cancers that currently do not have effective therapies, today reported preliminary results from a collaborative genomics analysis that will be used to optimize patient selection for Atrin’s upcoming ATRN-119 clinical trial. This genomics analysis was a result of Atrin’s collaboration with Predictive Technology Group to utilize next-generation genomics capabilities to improve predictive selection of clinical study patients most likely to respond and least likely to experience side effects from treatment with Atrin’s DDR drug candidates.

Atrin and Predictive have been jointly developing proprietary approaches to better identify patients with specific mutations that drive cancer tumor growth, regardless of tumor type, and who are most likely to clinically respond to synthetically-lethal anti-cancer therapies. Predictive’s genomics capabilities were added to Atrin’s existing proprietary proteomic and medicinal chemistry technologies to improve targeting of DDR proteins that are active in cancer cells and relatively inactive in healthy cells, ahead of Atrin’s initiation of a Phase 1/2a clinical study of ATRN-119, Atrin’s lead oral drug candidate.
Predictive is using a genomic data base analytics approach to help with patient selection, to increase efficiencies and quality of clinical trials, and to shorten time to market for Atrin’s drug candidates. Atrin’s pipeline also includes preclinical drug candidates in development for glioblastoma and hematological disorders that are being advanced towards IND enabling studies.
Oren Gilad, Ph.D., President and Chief Executive Officer of Atrin Pharmaceuticals, noted: “Our collaboration with Predictive, as shown in this genomics analysis, is already resulting in improved targeting of eligible patients for the upcoming Phase 1/2a ATRN-119 clinical study, and could potentially result in adoption of a new diagnostic for this type of anti-cancer treatment. Predictive’s unique genomic insights and modeling provide Atrin with enhanced diagnostic tools to accelerate Atrin’s DDR therapies and studies.” Atrin currently expects initiation of the ATRN-119 Phase 1/2a study in 2020, with a first interim clinical readout in 2021.
Bradley Robinson, President and Chief Executive Officer of Predictive Technology Group, stated: “We are pleased to work with Atrin; their cutting-edge work in discovering and advancing DDR therapies will benefit cancer patients with unmet medical needs. We believe that the Atrin collaboration is a ‘game changer’ that will result in improved design and faster clinical advancement of multiple individualized, precision oncology treatments. By combining our state-of-the-art proprietary screening assay and related artificial intelligence capabilities with Atrin's breakthrough DDR therapy candidates, we have the potential to become a leader in development of improved personalized oncology therapies. Both of Predictive’s main entities, Predictive Laboratories and Predictive Analytics, are involved in this ongoing DDR research with Atrin.”
Cancer is genomic disease; cancer tumors typically develop when otherwise healthy cells acquire mutations in key “driver genes.” These cancer-causing mutations alter pathways regulating cellular growth and interactions with surrounding tissues. Understanding the specific gene mutations underlying tumor formation is frequently more important than location of the cancer in selecting personalized anti-cancer therapies.
The key to successful cancer therapy is matching specific cancer mutations with efficient and targeted therapies. Multiple benign diseases, cancer-predisposition syndromes, and cancers have now been linked to mutations in DDR genes. DDR is a clinically validated therapeutic approach, following the commercial approval of multiple blockbuster Poly ADP Ribose Polymerase (PARP) inhibitor products. DDR drugs already represent a multi-billion-dollar market, and it is expected that DDR drugs may ultimately be used to treat over 200 different cancer targets, if a full set of complementary patient-targeting biomarkers are successfully developed and adopted for commercial use.
Preliminary results from the collaborative genomics analysis using Predictive’s proprietary assays in patients with a specific tumor type found an excess of DDR mutations in cancer cells compared with normal tissue. The analysis identified 92 genes as protein responders to ATRN-119 treatment, of which 18 genes are known TIER 1 cancer-driver genes, and well-characterized mutations were found in three dominant genes. Both in vitro and animal studies have confirmed synthetically-lethal interactions between ATRN-119 treatment and alteration of these three key cancer-causing genes. The overlap between DDR genes responding to ATRN-119 and those mutated in cancer cells suggest that genetic markers underlying response and resistance will be critical to optimizing patient selection in ATRN-119 clinical studies, by increasing clinical efficacy and minimizing systemic toxicities.
Under the terms of the original Atrin-Predictive collaboration agreement, both companies will continue to contribute to the identification of additional druggable targets and pathways, both inside and outside of DDR, to treat a broad group of target indications, particularly in women’s health.
About Atrin Pharmaceuticals
Atrin Pharmaceuticals, based in Doylestown PA, is a private biotech company focused on discovering and developing proprietary precision cancer therapeutics targeting inhibition of DNA Damage and Repair (DDR) proteins for first-line treatment of cancers. Atrin’s technologies and DDR product pipeline represent a new drug development approach for treating solid and other cancers that currently have limited or ineffective therapies by targeting inhibition of specific proteins that are active in cancer cells and relatively inactive in healthy tissue. For more information, visit [url]www.atrinpharma.com[/URL].
About Predictive Technology Group, Inc.
Predictive Technology Group (OTC PINK: PRED) aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Analytics, Predictive Biotech and Predictive Therapeutics. For more information, visit [url]www.predtechgroup.com[/URL].
Forward-Looking Statements:
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.


Contacts:
For more information, visit [url]www.atrinpharma.com[/URL] [url]www.predtechgroup.com[/URL] or contact Investor Relations:

For Atrin:

Media Contact
Michael King
3705 Old Easton Road
Doylestown PA, 18902
info@atrinpharma.com
For Predictive Technology Group:

Media Contact
Patrick Bursey
LifeSci Public Relations
pbursey@lifescipublicrelations.com
646-876-4932
Investor Contact
Jeremy Feffer
LifeSci Advisors
jeremy@lifesciadvisors.com
212-915-2568
[/FONT]

 

[brucefan]

[FONT=&quot]Endometriosis Risk Test ARTguide Shows Promising Early Beta Results

[/FONT]https://endometriosisnews.com/2020/...is-shows-promising-interim-beta-test-results/

 

[brucefan]

[FONT=&quot][h=1]Predictive Technology Group Addresses Use of Mesenchymal Stem Cells in Treatment of Secondary Issues Related to Coronavirus[/h]


[/FONT]
[FONT=&quot]

SALT LAKE CITY, March 17, 2020 (GLOBE NEWSWIRE) -- Predictive Technology Group (OTC PINK: PRED) (“Predictive” or “The Company”), today announced that last week it began communication with domestic and international agencies and groups to be a supplier of mesenchymal stem cells (MSCs) for the potential clinical treatment of patients suffering from secondary issues related to the coronavirus (COVID-19). In other related news today the American Society of Interventional Pain Physicians (ASIPP) issued a statement on COVID-19, discussing practices and urging authorities to approve expanded umbilical cord stem cell infusions as a treatment. WWW.asipp.org/asipp-updates/STATEMENT-FROM-ASIPP-ON-COVID-19

ChinaXiv recently reported (March 2, 2020) the outcomes of seven patients with COVID-19 pneumonia enrolled in a clinical trial at Beijing YouAn Hospital, China. The clinical outcomes, as well as changes in inflammatory and immune function levels, and adverse effects of the enrolled patients were assessed over the 14 days following MSC injection. The patients were treated with MSCs derived from the Wharton’s jelly layer of the umbilical cord. The pulmonary function and symptoms of all seven patients with COVID-19 pneumonia were significantly improved within 2 days of the MSC transplantation.
Utilizing regenerative medicine technology with the administration of MSCs may help mitigate underlying COVID-19 associated lung damage. While this treatment is not a method to vaccinate nor cure the virus, the results reported in this publication indicate that infected patients may be more likely to combat and survive the related secondary issues of a COVID-19 infection if regenerative technologies are applied.
“Given our expertise and proprietary processes for isolating the MSC’s from source tissue, combined with our strong safety record in delivering tens of thousands of allografts to the market, it is not surprising that we have received a high number of inquiries regarding our potential involvement with this global health crisis,” said Bradley Robinson, CEO of Predictive Technology Group. “We are watching the development of clinical trials from around the world and remain poised to help in any we can, pending regulatory guidance. Our experience and capital investments over the past few years has equipped us with the expertise and ability to scale to meet demand,” added Robinson.
MSCs have the ability to differentiate into a variety of cell types and are able to resist viral attacks with the expression of interferon gamma stimulated genes (ISGs). With the ability to express ISGs, stem cells would be expected to survive even when transplanted into a patient with an active COVID-19 infection. Stem cells rejuvenate and regenerate cells in the body through various processes involving reduction of inflammation, secretion of substances that protect cells, transfer of mitochondria, reduction of cell death, anti-oxidative effects and improvement of immune system function. These effects are likely to increase survival in patients infected with COVID-19.
Additionally, there is evidence of stem cells aiding in the protection against viral infection. The influenza virus A/H5N1 is known to cause acute lung injury. With the injection of human MSCs, A/H5N1 was reduced in mice and the treatment increased rates of survival (Chan, et al, PNAS 113:3621, 2016).
Umbilical cord tissue is particularly rich in MSCs, which is why many parents choose to store them. As new clinical therapies are discovered, the importance of storing stem cells from perinatal tissue (umbilical cord and placenta) will become a critical source for individuals needing stem cell therapies in the future.
Predictive Technology Group was the first to market and is the current market leader in the United States for the procurement and processing of umbilical cord tissue for clinical use. Predictive has operated its FDA-compliant commercial biologics manufacturing facility for several years. This facility is cGMP and cGTP compliant, ISO13485 certified, and FDA registered. All clinical manufacturing occurs in an ISO 7 certified sterile cleanroom with extensive and advanced testing to assure the absence of contamination.
"We are well positioned to have the procurement, processing and cell culturing expertise and scale to offer stem cell therapy for secondary issues related to COVID-19 infections in both domestic and international markets. While effective vaccines are being developed, US-based stem cell transplants represent a real opportunity to fight the virus and increase survival rates with patients infected worldwide,” Bradley Robinson added.

As the major commercial supplier of umbilical cord MSCs in the United States, Predictive is well positioned to continue its leadership role in ensuring a stable supply of this potentially life-saving intervention that has been associated with promoting the regeneration and repair of lung tissue damaged by acute respiratory viral infections, such as those caused by COVID-19. The company plans to evaluate potential research and commercial collaboration opportunities to supply stem cells either directly through Predictive, or in collaboration with other private and/or public entities.
About Predictive Technology Group, Inc.
Predictive Technology Group aims to revolutionize and personalize precision patient care. The Company’s entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests, as well as companion therapeutics, in order to support a patient from diagnosis through treatment. The Companies’ tests and products empower clinicians to provide their patients with the highest level of care. Predictive’s subsidiaries include Predictive Laboratories, Predictive Biotech and Predictive Therapeutics.
For more information, visit www.predtechgroup.com



GlobeNewswireMarch 17, 2020





[/FONT]

 

[brucefan]

https://predictivelabs.com/assurance-ab-covid19/